Newsbenzinga
MBX Biosciences Announces First Patient Dosed In Pivotal Phase 3 oPTimize Clinical Trial Evaluating Once-Weekly Canvuparatide For Treatment Of Chronic Hypoparathyroidism
· Published
Article summary
Please check the source for details.
An excerpt from the original article.
Comments —
Loading comments…